US2023045633A1PendingUtilityA1

Method for reducing lung inflammation

58
Assignee: Respirion Pharmaceuticals Pty LtdPriority: Jun 20, 2017Filed: Sep 28, 2022Published: Feb 9, 2023
Est. expiryJun 20, 2037(~10.9 yrs left)· nominal 20-yr term from priority
Inventors:Barry Spencer Clements
A61K 31/198A61P 29/00A61K 47/183A61K 9/0078A61P 11/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating or preventing inflammation in the lung by administering a high concentration of an inhaled chelating agent.

Claims

exact text as granted — not AI-modified
1 . An inhalable formulation containing a high concentration of a chelating agent. 
     
     
         2 . The formulation of  claim 1 , wherein the concentration of chelating agent is greater than 37.5 mg/dose. 
     
     
         3 . The formulation of  claim 1 , wherein the concentration of chelating agent is greater than 50 mg/dose. 
     
     
         4 . The formulation of  claim 1 , wherein the concentration of chelating agent is between 37.5 mg/dose and 300 mg/dose. 
     
     
         5 . The formulation of  claim 1 , wherein the concentration of chelating agent is between 50 mg/dose and 300 mg/dose. 
     
     
         6 . The formulation of  claim 1 , wherein chelating agent is provided up to a total dose of about 1,200 mg/day. 
     
     
         7 . The formulation of  claim 1 , wherein the chelating agent is CaEDTA. 
     
     
         8 . The formulation of  claim 1 , wherein the chelating agent is combined with tris(hydroxymethyl)aminomethane (TRIS). 
     
     
         9 . A kit for treating or preventing inflammation in the lung containing (i) an inhalable formulation containing a high concentration of a chelating agent; and (ii) instructions for use.

Join the waitlist — get patent alerts

Track US2023045633A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.